載入中
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
前收盤價
US$7.56
+US$0.02 · +0.27%
盤中時間採用ET。市場資料可能有所延遲。
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
日內區間
目前US$7.56
52週區間
目前US$7.56
盤中時間採用ET。市場資料可能有所延遲。
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
日內區間
目前US$7.56
52週區間
目前US$7.56
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5182.3萬 USD | 6372.3萬 USD | 5844.3萬 USD | 5149.4萬 USD | 4352.2萬 USD |
| 銷貨成本 | 657.4萬 USD | 562.6萬 USD | 528.1萬 USD | 454萬 USD | 440.6萬 USD |
| 毛利 | 4524.9萬 USD | 5809.7萬 USD | 5316.2萬 USD | 4695.4萬 USD | 3911.6萬 USD |
| 研究與開發 | 1.97億 USD | 1.28億 USD | 6105.5萬 USD | 5346.2萬 USD | 5008.3萬 USD |
| 銷售、一般及管理費用 | 1.18億 USD | 1.02億 USD | 7448.9萬 USD | 7214.6萬 USD | 6707萬 USD |
| 營業費用 | 3.15億 USD | 2.3億 USD | 1.36億 USD | 1.26億 USD | 1.17億 USD |
| 利息收入 | 1835.5萬 USD | 2028.2萬 USD | 398.3萬 USD | 79.8萬 USD | 3.3萬 USD |
| 利息支出 | 1183.5萬 USD | 1357.7萬 USD | 1133.8萬 USD | 702.2萬 USD | 667.1萬 USD |
| 折舊和攤銷 | 432.3萬 USD | 378.6萬 USD | 298.3萬 USD | 210.9萬 USD | 242.1萬 USD |
| 營業利益 | −2.7億 USD | −1.72億 USD | −8238.2萬 USD | −7865.4萬 USD | −7803.7萬 USD |
| 淨利 | −2.66億 USD | −1.94億 USD | −8073.6萬 USD | −7103.8萬 USD | −655.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6962.14萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4229.8萬0.05%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF2138.52萬0.02%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO1241.85萬0.07%180億 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO1240.76萬0.09%139.17億 USD0.24%US$353.71-0.86%
Invesco Pharmaceuticals ETFPJP1222.64萬2.23%5.48億 USD0.58%US$123.44+0.46%
Dimensional - US Small Cap ETFDFAS937.21萬0.03%338.69億 USD0.31%US$78.17-0.23%
Schwab U.S. Small-Cap ETFSCHA734.73萬0.03%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOInvesco Pharmaceuticals ETFPJPDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
